Why the study?
Do new oral anticoagulants reduce stroke risk compared to warfarin in patients with nonvalvular atrial fibrillation?
Do new oral anticoagulants reduce stroke risk compared to warfarin in patients with nonvalvular atrial fibrillation?
New oral anticoagulants provide a more convenient alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, though clinicians must weigh the increased risk of gastrointestinal bleeding with certain agents.
Answers are grounded in this paper and cite their sources.
May aid DOAC selection for nonvalvular AF; leaves open individualized bleeding risk assessments.
Four new oral anticoagulants have been approved for reducing stroke risk in patients with nonvalvular atrial fibrillation. Compared with warfarin, these agents offer a more predictable dose response with fewer food and drug interactions and no regular blood monitoring, although some of the drugs have an increased risk of major gastrointestinal bleeding. This article reviews the new drugs.
No takes yet. Share an insight, caveat, or question.
Holden et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: